Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. A bunch of people I know (including me) have gotten sick ...

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from ...

Lilly said patients must refill their prescriptions of the two higher-dose vials within 45 days of their first fill to get the same pricing, and would otherwise have to pay as much as $699 for ...

Shares of the Indianapolis-based drugmaker rose 2.3% to $902.42. The launch of Lilly's vials expands options for patients who choose to pay cash through the drugmaker's direct-to-consumer website ...

Regeneron (REGN) announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have profound genetic hearing loss due to variants of the ...

Lilly Offers Weight-Loss Drugs in Vials at a Discount to Fight Competition By Patrick Wingrove and Sriparna Roy (Reuters) -Eli Lilly said on Tuesday it cut the price for vials of its weight-loss ...

Regeneron has moved closer to a regulatory filing for its BCMAxCD3 bispecific antibody linvoseltamab, the first of a series of bispecifics that is spearheading its oncology pipeline. New data from ...

The aforementioned therapies and other drugs like Regeneron’s linvoseltamab are all being tested in pivotal trials as second- or third-line therapies. So, GSK’s window of opportunity with ...

Introduction: Only in recent years has balloon kyphoplasty gained significance in the treatment of vertebral fractures as an adequate minimally invasive vertebral stabilization technique ...

FDA decision expected by July 30, 2025TARRYTOWN, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...